Observational cross-sectional study revealing less aggressive treatment in Japanese elderly than nonelderly patients with rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 16, Issue 8, 2010, Pages 370-374

  Ogasawara, Michihiro ^a   Tamura, Naoto ^a   Onuma, Shin ^a   Kusaoi, Makio ^a   Sekiya, Fumio ^a   Matsudaira, Ran ^a   Kempe, Kazuo ^a   Yamaji, Ken ^a   Takasaki, Yoshinari ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

aging; disease modifying antirheumatic drugs; elderly; methotrexate; rheumatoid arthritis

Indexed keywords

AURANOFIN; BUCILLAMINE; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; PENICILLAMINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STROMELYSIN; TACROLIMUS;

ADULT; AGED; ARTICLE; FEMALE; GERIATRIC CARE; HEALTH STATUS; HUMAN; JAPANESE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 3; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOID FACTOR;

EID: 78650419954     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181fe8b37     Document Type: Article

References (25)

1. Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2004;43:906-914.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46:328-346.
3. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34-45.
4. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 1992;35:129-137.
5. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
6. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46: 1443-1450.
7. El Desoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 14:488-498.
8. Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med. 2002;18:577-592.
9. Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am. 2007;33:197-217.
10. Díaz-Borjón A. Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging. 2009;26:273-293.
11. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287-2293.
12. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1074-1081.
13. Harrison MJ, Kim CA, Silverberg M, et al. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? J Rheumatol. 2005;32:1243-1248.
14. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-2300.
15. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65:1226-1229.
16. Schmajuk G, Schneeweiss S, Katz JN, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007;57:928-934.
17. Genevay S, Finckh A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;57:679-685.
18. Oyama T, Kohno N, Yokoyama A, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung. 1997;175:379-385.
19. Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med. 2004;98:1131-1137.
20. Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the Banchor drug[ for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 21(5 Suppl 31):S179-S185.
21. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol. 2002;29:2521-2524.
22. Van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis. 2007;66: 1356-1362.
23. Suzuki Y. Methotrexate for the treatment of rheumatoid arthritis in JapanVmuch more still remains to be resolved. Nippon Rinsho. 2002;60:2331-2338.
24. Meyer O, de Bandt M, Berthelot JM, et al. Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy. Joint Bone Spine. 2007;74:73-78.
25. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784.